News

The future of AI in biologics drug discovery

•

June 5, 2023

By Sam DeLuca, Ph.D. With Steven Lewis, Ph.D. and Lucas Nivon, Ph.D. In our previous article in March 2023, we discussed our experience benchmarking publicly available AI protein design tools and exploring their real …

The impact of new protein AI tools on real-world biologics discovery

•

March 29, 2023

Protein AI tools are useful for aggressive protein design, while physics based tools continue to be required for re-design of natural proteins for most cases By Steven Lewis, Dan Farrell, Brandon Frenz, …

Cyrus Biotechnology Scientist Erik Procko and the company’s lead ACE2-Fc Fusion protein COVID-19 therapeutic are featured in Science news article highlighting the exciting potential of decoy receptor drugs in fighting SARS-CoV-2, and other viral infections – (Science.com)

•

February 6, 2023

https://www.science.org/content/article/protein-decoys-viruses-may-battle-covid-19-and-more

OpenFold AI Research Consortium Welcomes 4 New Members: Bayer, Dassault, CHARM Therapeutics and BaseCamp Research

•

November 22, 2022

OpenFold, a non-profit artificial intelligence (AI) research consortium whose goal is to develop free and open source software tools for biology and drug discovery, today announced the addition of four new industry members: …

Foundation Models for Proteins: Cyrus, OpenFold and the future of biologics

•

October 3, 2022

Recent advances in the architecture and scale of AI are leading us from the era of narrowly focused AI (e.g. text auto-complete, immune epitope prediction in a protein sequence, antibody domain detection) …

Cyrus Scientists Develop Tool for Peptide Design with Non-canonical Amino Acids

•

August 16, 2022

https://www.frontiersin.org/articles/10.3389/fmolb.2022.848689/full

Career Insights.

Join CyrusBio and provide solutionsfor 120+ biotech/pharma companies.